Only weeks ago, Merck's I-O superstar Keytruda whiffed in a key lung cancer trial. Now the therapy is facing pushback from England's cost watchdog.
As JPM kicks into gear, Novartis CEO Vas Narasimhan and British health officials unveiled a new access agreement on inclisiran.
British cost watchdogs have rejected Akcea's Waylivra on cost-effectiveness concerns, but the company says it'll keep working with NICE.
Like many a rejuvenation plan, CEO Paul Hudson's blueprint for Sanofi includes hefty cost cutting, with jobs, marketing and more on the block.
ICER is still concerned about high prices of next-generation RA drugs—a stance that's not going over well among RA drugmakers and patient groups.
GW Pharma just won the industry's first cannabinoid nods from NICE, which endorsed Epidyolex for a rare epilepsy and Sativex for MS muscle spasticity.
Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.
ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.
ICER is calling out drugmakers for price increases that are not supported by clinical data, But some of the companies have bones to pick.
Riding high on FDA and EU approvals in triple-negative breast cancer, Roche’s Tecentriq hoped for a win from NICE. The drugmaker didn’t get it.